Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300.

Dysregulated AKT signaling in osteosarcoma enhances dependency on EP300, with sensitivity to EP300 degradation linked to AKT activation and relocalization of epigenetic regulators.

• Why it matters: Understanding the molecular dependencies of osteosarcoma can reveal targeted vulnerabilities for therapy, especially in genetically defined subgroups with pathway dysregulation.
• What they did: The study used a selective EP300 degrader (JQAD1) and chemical-genetic analysis across cancer cell lines, identifying that AKT-dysregulated osteosarcoma is sensitive to EP300 loss, with synergy observed when combined with AKT inhibitors.
• The result: Findings suggest co-targeting EP300 and AKT may effectively suppress growth in osteosarcoma with elevated protein synthesis, providing a basis for tailored therapeutic strategies.